Imbruvica ibrutinib: Additional Phase III data

Imbruvica is approved in the U.S. to treat CLL in patients who have the chromosome 17p deletion and in patients who have received >=1 prior therapy and to treat Waldenstrom’s macroglobulinemia. The pr...